GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed…
HAI Community Presents Learning Journals Inspired by the Work of Cassian Grant
New York, NY, July 17, 2025 (GLOBE NEWSWIRE) -- HAI Community, the…